PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Sickle cell disease - Market size and forecast 2018-2023
• Thalassemia - Market size and forecast 2018-2023
• Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: VENDOR LANDSCAPE
• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ApoPharma
• Bristol-Myers Squibb
• Emmaus Medical
• Medunik USA
• Novartis

PART 14: APPENDIX
• Research methodology
• List of abbreviations

List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global hematology drugs market
Exhibit 03: Segments of global hematology drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Sickle cell disease - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Sickle cell disease - Year-over-year growth 2019-2023 (%)
Exhibit 22: Thalassemia - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Thalassemia - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Therapeutics that have received the orphan drug designation from the US FDA recently
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: ApoPharma - Vendor overview
Exhibit 48: ApoPharma - Business segments
Exhibit 49: ApoPharma - Organizational developments
Exhibit 50: ApoPharma - Key offerings
Exhibit 51: ApoPharma - Key customers
Exhibit 52: Bristol-Myers Squibb - Vendor overview
Exhibit 53: Bristol-Myers Squibb - Business segments
Exhibit 54: Bristol-Myers Squibb - Organizational developments
Exhibit 55: Bristol-Myers Squibb - Geographic focus
Exhibit 56: Bristol-Myers Squibb - Key offerings
Exhibit 57: Bristol-Myers Squibb - Key customers
Exhibit 58: Emmaus Medical - Vendor overview
Exhibit 59: Emmaus Medical - Business segments
Exhibit 60: Emmaus Medical - Organizational developments
Exhibit 61: Emmaus Medical - Geographic focus
Exhibit 62: Emmaus Medical - Key offerings
Exhibit 63: Emmaus Medical - Key customers
Exhibit 64: Medunik USA - Vendor overview
Exhibit 65: Medunik USA - Business segments
Exhibit 66: Medunik USA - Organizational developments
Exhibit 67: Medunik USA - Key offerings
Exhibit 68: Medunik USA - Key customers
Exhibit 69: Novartis - Vendor overview
Exhibit 70: Novartis - Business segments
Exhibit 71: Novartis - Organizational developments
Exhibit 72: Novartis - Geographic focus
Exhibit 73: Novartis - Segment focus
Exhibit 74: Novartis - Key offerings
Exhibit 75: Novartis - Key customers
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations

Companies Mentioned
. ApoPharma
. Bristol-Myers Squibb
. Emmaus Medical
. Medunik USA
. Novartis